Currently, the clinical drugs for IBD mainly include 5-aminosalicylic acid (5-ASA), corticosteroids, immunosuppressants, and TNF-α inhibitors, which have limited efficacy and are prone to clinical adverse reactions, such as anemia, rash, and liver, as well as pancreas injury, and even lead to adverse events, such as infection, nervous system diseases, and malignant tumors. Here, TNF is linked to inflammatory bowel disease.